PharmaBg
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma Wins 5-Year Extension of Patent on Main Breast Cancer Treatment Drug Nerlynx - Los Angeles Business Journal
La EMA recomienda no aprobar el fármaco de Puma Biotech
Puma Biotechnology
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma – PHARMA
Puma – PHARMA
El negocio bursátil de PUMA BIOTECHNOLOGY – Observatorio de biopolitica
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
Ex-Puma exec charged with insider trading, hit with criminal charges | Fierce Biotech
Puma Biotechnology
Compra Acciones de Puma Biotechnology Inc y Comprueba ($PBYI) su Precio de Mercado en eToro.
Puma Biotechnology
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha
Puma – PHARMA
Puma Biotechnology Surging
Puma Men – PHARMA
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology, Inc. | LinkedIn
Buy Hering Pharma Muira Puma Mother Tincture Q 30ml | ShopHealthy.in
PUMA BIOTECHNOLOGY, INC. : Precios y cotizaciones Acción | PBYI | US74587V1070 | MarketScreener
Resumen: Puma Biotechnology y Pierre Fabre firman acuerdo de licencia exclusiva para desarrollar y comercializar NERLYNX® (neratinib) en Europa | Business Wire
Puma – PHARMA
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
